A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

Start Date11 Apr 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT05726292

/ RecruitingPhase 2IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Start Date06 Jan 2025

Sponsor / Collaborator

The University of Chicago

NCT05257408

/ Active, not recruitingPhase 3

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Start Date29 Jun 2022

Sponsor / Collaborator

Corcept Therapeutics, Inc.

[+1]

100 Clinical Results associated with Relacorilant

100 Translational Medicine associated with Relacorilant

100 Patents (Medical) associated with Relacorilant

Literatures (Medical) associated with Relacorilant

04 Nov 2024·ONCOLOGIST

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Article

Author: Leal, Alexis D ; Skeel, Roland T ; Fountzilas, Christos ; Pashova, Hristina ; Mann, Grace ; Alese, Olatunji B ; Oberstein, Paul E ; Huyck, Timothy K ; Kio, Ebenezer A ; Noonan, Anne M ; Chiorean, Elena Gabriela ; Bahary, Nathan ; Borazanci, Erkut H ; Lee, Valerie ; Philip, Philip A ; Chung, Vincent ; Wainberg, Zev A ; Hanna, Wahid T ; Cardin, Dana B

Abstract:

Background:

Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines.

Patients and Methods:

In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.

Results:

Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.

Conclusion:

Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

02 Aug 2024·Expert Review of Anticancer Therapy

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives

Review

Author: Marchetti, Claudia ; Ghizzoni, Viola ; Scambia, Giovanni ; Salutari, Vanda ; Vertechy, Laura ; Giudice, Elena ; Fagotti, Anna ; Sassu, Carolina Maria ; Carbone, Maria Vittoria

INTRODUCTION:

Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.

AREAS COVERED:

Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.

EXPERT OPINION:

Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.

03 Jun 2024·Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer

Article

Author: O'Donnell, Peter H. ; Szmulewitz, Russell Z. ; Serritella, Anthony V. ; Stadler, Walter M. ; Sweis, Randy F. ; Desai, Kunal B.

Abstract:

Purpose::

The majority of patients with metastatic prostate cancer who receive androgen-deprivation therapy and androgen receptor (AR) signaling inhibitors (ARSI) progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI resistance. This single-arm phase I trial assessed safety and pharmacokinetic (PK) feasibility of a combined AR antagonist (enzalutamide) and selective GR modulator (relacorilant) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Patients and Methods::

This was a phase I trial (NCT03674814) of relacorilant and enzalutamide in patients with refractory mCRPC enrolled using a 6+3 design. The enzalutamide dose was kept constant at 120 mg/d with escalating doses of relacorilant based on safety and PK measures in cohorts of ≥6 patients. The primary objective was safety and establishment of pharmacologically active doses. Secondary objectives were related to antitumor activity.

Results::

Thirty-five patients with mCRPC were enrolled. Twenty-three were accrued across three dose cohorts in the dose-escalation phase, and 12 enrolled at the recommended phase II dose. The combination was generally well tolerated, safe, and achieved desirable enzalutamide PK. RP2D of 120 + 150 mg/d, respectively, was established. Median time on study was 2.2 months with four patients remaining on study for longer than 11 months. Four of 12 evaluable patients had a prostate-specific antigen (PSA) partial response.

Conclusions::

This is the first prospective trial combining an AR antagonist and a nonsteroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.

News (Medical) associated with Relacorilant

06 Jun 2025

·www.biospace.com

Corcept Claims Survival Benefit in ALS Despite Missed Endpoint

iStock, cagkansayin Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative. Corcept Therapeutics ’ investigational cortisol modulator dazucorilant failed to boost functional performance in patients with amyotrophic lateral sclerosis—but the biotech dug into the data Thursday and came away with overall survival benefits. Analysts at Truist Securities called the Phase II readout a “mixed bag” in an investor note on Thursday, adding that aside from the missed primary endpoint, dazucorilant also elicited “increased” gastrointestinal adverse events. “We would have liked to see some QoL [quality of life] assessments to better gauge commercial potential as discontinuation rates” seemed higher in the dazucorilant group versus placebo, they said. Still, Truist considered Thursday’s readout to be only “incremental” to Corcept’s overall stock narrative. The analyst firm does not include dazucorilant in its valuation for the biotech. Thursday’s data, presented at the 2025 annual meeting of the European Network to Cure ALS, showed no statistical separation between dazucorilant and placebo patients in terms of scores on the ALS Functional Rating Scale-Revised , a disease-specific severity score that evaluates patients’ disability and respiratory function, among other metrics. However, an exploratory analysis found that dazucorilant treatment significantly improved overall survival. At 24 weeks, five of 82 patients on placebo died, as opposed none of the 83 patients in the dazucorilant arm. At one year, treatment with dazucorilant cut the risk of death by 84% versus placebo. The biotech called this effect “pronounced” in its Thursday release. Given the mixed mid-stage findings, Corcept is currently “working with regulatory authorities” to determine the best path forward for dazucorilant, Bill Guyer, the company’s chief development officer, said in a prepared statement on Thursday. The ALS readout comes after Corcept earlier this week unveiled Phase III data for its selective glucocorticoid receptor antagonist relacorilant, which it combined with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. The findings, revealed in a late-breaking presentation at the recently concluded 2025 conference of the American Society of Clinical Oncology, showed that the relacorilant regimen cut the risk of disease progression by 30% versus nab-paclitaxel alone. Progression-free survival, the study’s primary endpoint, improved 29% in relacorilant-treated patients versus controls. As in the case of dazucorilant in ALS however, Truist analysts flagged potential safety concerns with relacorilant. “Based on investor conversations, concerns may be around tolerability pro relacorilant, which is numerically higher than nab-pac alone,” the analysts wrote in a June 2 note. “Nab-pac” is BMS’s formulation of the chemotherapy paclitaxel, sold as Abraxane. However, Truist noted that these safety signals could be due to the “greater duration of exposure to nab-pac” in patients receiving the combo therapy. “When adjusted for duration of exposure, common AEs including neutropenia and anemia are comparable between study arms,” they said. Overall, the analysts found relacorilant’s profile “favorable,” adding that they “expect approval with commercial traction.” Corcept plans to submit a regulatory application for relacorilant in the third quarter of this year.

Clinical ResultPhase 2ASCOPhase 3

05 Jun 2025

·www.fiercebiotech.com

Corcept unveils promising survival data from failed phase 2 ALS trial

The biopharma has since conducted an analysis at 12 months that it said showed this survival benefit has continued.\n Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data.The biopharma revealed in December 2024 that the drug, called dazucorilant, had failed to demonstrate a reduction in the decline in motor skills and other functional criteria, while being linked to “substantially more gastrointestinal upset.” The midstage study saw 249 patients across the U.S., Canada and Europe receive either 150 mg or 300 mg of dazucorilant or placebo daily for 24 weeks.In a presentation at the European Network to Cure ALS 2025 annual meeting this week, Corcept included a table showing that the decline as measured by a functionality scale was broadly the same across both dazucorilant cohorts and the placebo group over 24 weeks.However, Corcept pointed out that patient survival—a secondary endpoint for the study—“significantly improved” among the 83 patients who received the 300 mg dazucorilant dose. None of these patients had died by week 24, Corcept noted, compared to two patients in the 150 mg arm and five patients who received placebo.The biopharma has since conducted an analysis at 12 months that it said showed this survival benefit has continued. Specifically, 14 patients in the 300 mg group had died by this point, compared to 23 deaths in the 150 mg group and 21 deaths in the placebo arm—equivalent to a hazard ratio of 0.16 for the 300 mg group and placebo groups.Speaking to Fierce at the American Society of Clinical Oncology meeting in Chicago this week, Adrian Jubb, M.D., Ph.D., Head of Oncology and Neurology Clinical Development at Corcept, said the company had not originally planned “to look at the data this way.”“Nonetheless, in a disease like this, when you see an endpoint that\'s really clinically meaningful, like survival, it makes you stop and think,” Jubb told Fierce. “And so we\'re now looking at the data in a much more positive light than simply a miss on a primary objective.” When it came to safety, this morning\'s data showed that 19% of patients in the 300 mg group experienced at least one severe treatment-emergent adverse event (TEAE), compared to 17% of the 150 mg group and 13% of the placebo cohort. No patients died as a result of a TEAE in the 300 mg group, compared to two patients in the 150 mg group and four patients in the placebo group. Overall, dazucorilant demonstrated “an acceptable safety profile,” according to Corcept, which pointed out that 92% of adverse events were mild to moderate in severity.“Medications that can extend life for patients with ALS are urgently needed,” Corcept’s Chief Development Officer Bill Guyer said in a June 5 statement. “We are working with regulatory authorities to determine the optimal path for advancing dazucorilant.”The Redwood City, California-based biotech markets the FDA-approved cortisol receptor blocker Korlym, also known as mifepristone, as a treatment for hyperglycemia caused by high cortisol levels in the blood. Corcept’s clinical-stage pipeline is headed up by relacorilant, an antiglucocorticoid that secured a phase 3 win in Cushing’s syndrome last year and is awaiting an FDA approval decision by the end of the year.The biotech was up more than 1.4% premarket Thursday morning on a $7.4 billion market cap.

Clinical ResultPhase 3Drug ApprovalPhase 2ASCO

15 May 2025

·www.prnewswire.com

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market. LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cushing's Disease Market Report According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024. In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034). Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years. The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others. In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism. In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026. In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome. Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies. Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years. Cushing's Disease Epidemiology Segmentation The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Cushing's Disease Total Diagnosed Prevalent Cases of Cushing's Disease Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease Age-Specific Diagnosed Prevalent Cases of Cushing's Disease Cushing's Disease Treatment Market The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels. Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include S IGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma. SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route. Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900). RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action. To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management Cushing's Disease Pipeline Therapies and Key Companies Relacorilant (CORT125134): Corcept Therapeutics Clofutriben (SPI-62): Sparrow Pharmaceuticals Atumelnant (CRN04894): Crinetics Pharmaceuticals Lu AG13909: H. Lundbeck ST-002: Stero Therapeutics Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials Cushing's Disease Market Dynamics The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR. Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM. However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies. Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth. Scope of the Cushing's Disease Market Report Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends Table of Contents Related Reports Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Cushing's Syndrome Pipeline Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Endogenous Cushing's Syndrome Market Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. Endogenous Cushing's Syndrome Pipeline Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugPhase 2

100 Deals associated with Relacorilant

External Link

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cushing Syndrome	NDA/BLA	United States	Corcept Therapeutics, Inc.	30 Dec 2024
Peritoneal Neoplasms	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Argentina	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Australia	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Belgium	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Brazil	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Canada	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	France	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Hungary	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Israel	Corcept Therapeutics, Inc.	29 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03776812 (CTgov)	Phase 2	Recurrent Platinum-Resistant Primary Peritoneal Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma ... View more	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	ahwkwqsetn(zowajedjwm) = skslwfhbdu ypnchlxiot (ibyricczpt, rxuvdaifdb - fkuneyfclh) View more	-	30 Apr 2025
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	ahwkwqsetn(zowajedjwm) = pvtnbjzqel ypnchlxiot (ibyricczpt, aurnnduogs - krgattslpq) View more
NCT03697109 (GRACE, CTgov)	Phase 3	Endogenous Cushing Syndrome	152	Relacorilant (Relacorilant (RW Phase))	cwttvfxjct = whvcwdiijs cgavuqbzjh (kxfycnxuxa, gbwnuzmkyy - ccscraaibn) View more	-	24 Apr 2025
				Placebo (Placebo (RW Phase))	cwttvfxjct = zoethyputi cgavuqbzjh (kxfycnxuxa, zyyjgjphpa - vxkrukmnxu) View more
NCT05257408 (ROSELLA, Company_Website) Manual	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	eqlfcgmcsz(fbcjenmpex) = kevymuconq snfykejyuf (uqhinchvzn ) Met View more	Positive	31 Mar 2025
				Nab-paclitaxel	eqlfcgmcsz(fbcjenmpex) = mjyezffozk snfykejyuf (uqhinchvzn ) Met View more
NCT03604198 (BusinessWire) Manual	Phase 3	Cushing Syndrome	116	Relacorilant	weyobosjzz(lwofaqpfqm) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. nsesdbdyos (nbouguawwy ) View more	Positive	16 Dec 2024
NCT03604198 (Company_Website) Manual	Phase 2	Cushing Syndrome	53	Relacorilant	dpahloqcyc(cqjhmibnxf) = kjabezvros fphsifqltx (meiaxlvfqo ) View more	Positive	25 Nov 2024
NCT04308590 (GRADIENT, Biospace) Manual	Phase 3	Cushing Syndrome	137	relacorilant	oeabxqntcx(eketjzdlef) = pbxzkcsuag bachrcvfqu (toajklheir ) Met	Positive	30 Oct 2024
				Placebo	oeabxqntcx(eketjzdlef) = jiyqlvpmqm bachrcvfqu (toajklheir ) Met
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	Phase 2	Cushing Syndrome factor VIII \| activated partial thromboplastin time \| platelet count ... View more	34	Relacorilant (Surgery)	cgeottxucy(bwbdrgkazc) = upohhtktjb czhgkakijd (gvmajzwfyz )	Positive	21 Sep 2024
NCT03697109 (GRACE, ENDO2024)	Phase 3	Cushing Syndrome	152	Relacorilant 100 mg QD	wvchfbkfmz(phvthivqft) = icunsjjdcq dnmachftja (kdltnupkgh, 6.7) View more	Positive	01 Jun 2024
NCT03697109 (GRACE, Company_Website) Manual	Phase 3	Cushing Syndrome	-	relacorilant	umijudygik(fcxixwganz) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo zfurfgtrho (mozbmyohfa ) Met View more	Positive	28 May 2024
				placebo
NCT03697109 (GRACE, GlobeNewswire) Manual	Phase 3	Endogenous Cushing Syndrome	152	relacorilant	ecvrssddan(josdmollaw) = fktckzlcoy ycyegmduxj (kqqvhbpkhx ) View more	Positive	22 Apr 2024
				relacorilant (withdrawal phase)	ecvrssddan(josdmollaw) = qhfcnfpeva ycyegmduxj (kqqvhbpkhx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis